Therapeutic value of glycosaminoglycans in cancer
Open Access
- 1 September 2006
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 5 (9), 2139-2148
- https://doi.org/10.1158/1535-7163.mct-06-0082
Abstract
Glycosaminoglycans are unbranched polysaccharides composed of repeating units of alternating uronic acids and amino sugars. Most glycosaminoglycans are covalently attached to core proteins to form proteoglycans. Posttranslational modifications result in specific motifs that bind to a large variety of ligands, thus regulating growth factor signaling, cellular behavior, inflammation, angiogenesis, and the proteolytic environment. Dysregulated expression of glycosaminoglycans is present in cancer and reported to correlate with clinical prognosis in several malignant neoplasms. Recent knowledge on the biological roles of these molecules in cancer biology, tumor angiogenesis, and metastasis has promoted the development of drugs targeting them. Pharmaceutical approaches include the use of chemically modified heparins and glycosaminoglycans with defined structures, combination of inhibitors of glycosaminoglycan biosynthesis and polyamine depletion, and biologically active glycosaminoglycan-binding peptides. In addition, glycosaminoglycans are used as tumor-specific delivery and targeting vehicles for toxins and chemotherapeutics. Encouraging results in animal studies and clinical trials show the clinical relevance of glycosaminoglycan-based drugs and the use of glycosaminoglycans as therapeutic targets. [Mol Cancer Ther 2006;5(9):2139–48]Keywords
Other Versions
This publication has 97 references indexed in Scilit:
- Constitutive and Accelerated Shedding of Murine Syndecan-1 Is Mediated by Cleavage of Its Core Protein at a Specific Juxtamembrane SiteBiochemistry, 2005
- Basement membrane proteoglycans: from cellar to ceilingNature Reviews Molecular Cell Biology, 2005
- A hyaluronan synthase suppressor, 4‐methylumbelliferone, inhibits liver metastasis of melanoma cellsFEBS Letters, 2005
- Tumour stem cells and drug resistanceNature Reviews Cancer, 2005
- Heparanase expression correlates with malignant potential in human colon cancerZeitschrift für Krebsforschung und Klinische Onkologie, 2004
- Expression of HYAL2 mRNA, hyaluronan and hyaluronidase in B‐cell non‐Hodgkin lymphoma: Relationship with tumor aggressivenessInternational Journal of Cancer, 2004
- Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanismsThe Journal of cell biology, 2004
- Inhibition of heparanase activity and heparanase‐induced angiogenesis by suramin analoguesInternational Journal of Cancer, 2003
- WISP-1 Binds to Decorin and BiglycanJournal of Biological Chemistry, 2001
- Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo.JCI Insight, 1998